GNS Healthcare Blog

This is the third in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.  

Regulatory approval of a drug does not immediately translate into premier market access or projected results. The reality is that the pressure on pharma companies from health plans and pharmacy benefit managers (PBMs) to provide evidence-based research on treatment efficacy and effectiveness before including drugs on their formularies is only increasing.

The earlier pharma companies can answer these asks, the better. The goal is...

The following is the second in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.

The success of clinical trials relies heavily on having enough of the right patients willing and able to participate. Unfortunately, achieving the levels of recruitment necessary to conduct successful trials is difficult – particularly in cancer and rare diseases trials.

One recent survey revealed that only one in three cancer patients were likely to enroll in a clinical trial. Less than half of those surveyed viewed...

The following is the first in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.

Biopharma companies and government funded research projects have produced stellar results over the years: from lifesaving drugs and to life improving therapies that benefit millions of patients. But these discoveries often come at a substantial financial cost and take many years to bring to market. In fact, the cost of bringing one drug from discovery to approval is currently estimated at between $1.8 and $3.0 billion.^[1]

In 2017, the American Cancer Society awarded $112 million for cancer research.^[1] The National Institute of Health FY17 budget for cancer research was nearly $6 billion.^[2]

Pharma companies are pouring billions of R&D dollars into developing new treatments for cancer and are looking for the best ways to maximize those investments. One of the, most effective research tools available and one increasingly leveraged by biopharma is artificial intelligence (AI), used to help unlock the complex mechanisms of cancer.

Oncology is an enormously complicated field, so it’s no surprise that...

The new year has just begun and the flurry of predictions for 2019 are popping up everywhere. Healthcare thought leaders have joined in offering their forecasts and ruminations around what we can expect over the next 12 months. We did the same and asked prominent thought leaders to offer their opinions in our prediction post earlier this year.

But what about the predictions made a year ago? How did the 2018 predictions actually turn out and what will continue into 2019? 

We took a look back to see what we could find. As expected, there were hits and misses but there were five that were on...

If “following the money” is the quickest path to the root of a trend, then 2019 promises to be the year artificial intelligence takes center stage in the healthcare industry.

By 2024, AI in the U.S. healthcare market is set to exceed $10 billion according to a recent Global Market Insights report.^[1] As nearly eight out of ten healthcare executives who responded to a recent cross-industry survey said their organizations are ramping up investments in big data analytics and AI, it should come as no surprise that the market is truly ramping up.^[2] Nearly 80 healthcare AI startups raised their...

Abraham Maslow famously said, “If all you have is a hammer, everything looks like a nail.”

With all the buzz surrounding artificial intelligence (AI), it’s tempting to view it as an all-encompassing tool that can be employed to solve healthcare’s myriad of problems. In fact, there are a number of debates taking place over what AI and machine learning (ML) can and can’t do. The reality is that there are a range of AI technologies that solve very different types of problems. There are distinct use cases for each type of AI, from advanced analytics to deep learning to causal AI. But as we begin...

Some experts estimate that between 60 to 80 percent of a person’s health condition is influenced by social factors, far outpacing the impact of direct clinical care¹.

Nutrition, housing, transportation, literacy and education, safety, language and social support are social determinants of health (SDOH) and are key drivers of health outcomes.

The World Health Organization defines SDOH as “the conditions in which people are born, grow, work, live, and age, and the wider set of forces and systems shaping the conditions of daily life.”²

Leaders across healthcare are recognizing the power of...

We asked industry thought leaders from across the healthcare ecosystem to weigh in on their predictions, hopes and ruminations for the year ahead.

From cancer therapy to data sharing to patient apps to affordability, we share some of 2019's most thoughtful predictions.

Here's what healthcare's thought leaders are saying.

During the holiday season, our thoughts turn gratefully to those who made our progress possible, our work enjoyable and our lives enriched.